Drugs for rare and end-of-life conditions get Scottish cash boost
This article was originally published in Scrip
Executive Summary
The Scottish government has allotted £80m to the New Medicines Fund, which is used to help pay for treatments for patients with rare or end-of-life conditions, for 2015-16. This is double the amount given to the fund in the previous year, and will help pay for the expected rise in the number of such products being recommended by the HTA body, the Scottish Medicines Consortium (SMC).
You may also be interested in...
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.
EU Countries Offered Funding To Contribute to African Regulatory Strengthening
Training projects are intended to strengthen the African regulatory environment, boost the capacity of the African Medicines Agency, facilitate regulatory reliance, and increase joint new drug assessments.